Literature DB >> 28270733

Nasopharyngeal non-intestinal-type adenocarcinoma: a case report and updated review of the literature.

C Jain1, L Caulley2, K I Macdonald2, B Purgina3, C K Lai3, B Esche4, S Johnson-Obaseki2.   

Abstract

BACKGROUND: Non-intestinal-type adenocarcinoma is a malignancy traditionally found in the sinonasal cavity. To our knowledge, this case is the first reported of this rare condition originating in the nasopharynx. CASE
PRESENTATION: A 67-year-old woman with nasopharyngeal non-intestinal-type adenocarcinoma, with an accompanying parapharyngeal mass received primary radiation treatment for both lesions. Her tumour subsequently persisted, with a concomitant conversion in pathology from a low- to a high-grade malignancy.
RESULTS: Non-intestinal-type and intestinal-type adenocarcinomas of the nasopharynx are extremely rare tumours and do not appear in the World Health Organization classification system. We review the pathophysiologic features of these malignancies and propose modifications to the current classification system.
CONCLUSIONS: Non-intestinal-type adenocarcinoma should be included in the differential diagnosis of nasopharyngeal masses. In our experience, this tumour in this location showed a partial response to primary radiation but later converted from a low- to a high-grade adenocarcinoma.

Entities:  

Keywords:  Non-intestinal adenocarcinoma; disease classifications; intestinal adenocarcinoma; nasopharynx; sinonasal cavity

Year:  2017        PMID: 28270733      PMCID: PMC5330639          DOI: 10.3747/co.24.3299

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  9 in total

1.  Update on sinonasal adenocarcinoma: classification and advances in immunophenotype and molecular genetic make-up.

Authors:  Ilmo Leivo
Journal:  Head Neck Pathol       Date:  2007-11-28

Review 2.  Sinonasal carcinomas: recent advances in molecular and phenotypic characterization and their clinical implications.

Authors:  Alessandro Franchi; Lucia Miligi; Annarita Palomba; Lucia Giovannetti; Marco Santucci
Journal:  Crit Rev Oncol Hematol       Date:  2010-09-25       Impact factor: 6.312

3.  Low-grade nonintestinal sinonasal adenocarcinoma: a diagnosis of exclusion.

Authors:  Feriyl Bhaijee; Jeffrey Carron; Diana Bell
Journal:  Ann Diagn Pathol       Date:  2011-03-10       Impact factor: 2.090

4.  A histologic and immunohistochemical study describing the diversity of tumors classified as sinonasal high-grade nonintestinal adenocarcinomas.

Authors:  Edward B Stelow; Vicky Y Jo; Stacey E Mills; Diane L Carlson
Journal:  Am J Surg Pathol       Date:  2011-07       Impact factor: 6.394

Review 5.  Adenocarcinoma of the upper aerodigestive tract.

Authors:  Edward B Stelow; Stacey E Mills; Vickie Y Jo; Diane L Carlson
Journal:  Adv Anat Pathol       Date:  2010-07       Impact factor: 3.875

6.  A Subset of Sinonasal Non-Intestinal Type Adenocarcinomas are Truly Seromucinous Adenocarcinomas: A Morphologic and Immunophenotypic Assessment and Description of a Novel Pitfall.

Authors:  Bibianna Purgina; Jassem M Bastaki; Umamaheswar Duvvuri; Raja R Seethala
Journal:  Head Neck Pathol       Date:  2015-02-19

7.  Sinonasal adenocarcinoma: evidence for histogenetic divergence of the enteric and nonenteric phenotypes.

Authors:  Hong-Ran Choi; Erich M Sturgis; Asif Rashid; Franco DeMonte; Mario A Luna; John G Batsakis; Adel K El-Naggar
Journal:  Hum Pathol       Date:  2003-11       Impact factor: 3.466

8.  A retrospective cohort study of nasopharyngeal adenocarcinoma: a rare histological type of nasopharyngeal cancer.

Authors:  Z M Guo; W W Liu; J H He
Journal:  Clin Otolaryngol       Date:  2009-08       Impact factor: 2.597

9.  The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7-/20+ phenotype is more specific than CDX2 antibody.

Authors:  Reyhan Bayrak; Hacer Haltas; Sibel Yenidunya
Journal:  Diagn Pathol       Date:  2012-01-23       Impact factor: 2.644

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.